Generics in Japan

Date: August 27, 2013
Pages: 36
Price:
US$ 350.00
License [?]:
Publisher: MarketLine
Report type: Brief Review
Delivery: E-mail Delivery (PDF)
ID: GDBE6BEE215EN
Leaflet:

Download PDF Leaflet

Generics in Japan
Introduction

Generics in Japan industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Japan generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights
  • For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The Japanese generics market had total revenues of $4.2bn in 2012, representing a compound annual growth rate (CAGR) of 5.3% between 2008 and 2012.
  • Market consumption volume increased with a CAGR of 8.4% between 2008-2012, to reach a total of 24.3% of total pharma volume in 2012.
  • The performance of the market is forecast to decelerate, with an anticipated CAGR of 4.1% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $5.1bn by the end of 2017.
Featuress

Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Japan

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Japan

Leading company profiles reveal details of key generics market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Japan generics market with five year forecasts by both value and volume

Macroeconomic indicators provide insight into general trends within the Japan economy

Key Questions Answered
  • What was the size of the Japan generics market by value in 2012?
  • What will be the size of the Japan generics market in 2017?
  • What factors are affecting the strength of competition in the Japan generics market?
  • How has the market performed over the last five years?
  • What are the main segments that make up Japan's generics market?
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Daiichi Sankyo Co., Ltd.
Nichi-iko Pharmaceutical
Sawai Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country Data
Appendix
Methodology
Industry associations
Related MarketLine research

LIST OF TABLES

Table 1: Japan generics market value: $ million, 2008–12
Table 2: Japan generics market volume: % of total pharma volume, 2008–12
Table 3: Japan generics market geography segmentation: $ million, 2012
Table 4: Japan generics market value forecast: $ million, 2012–17
Table 5: Japan generics market volume forecast: % of total pharma volume, 2012–17
Table 6: Daiichi Sankyo Co., Ltd.: key facts
Table 7: Daiichi Sankyo Co., Ltd.: key financials ($)
Table 8: Daiichi Sankyo Co., Ltd.: key financials (¥)
Table 9: Daiichi Sankyo Co., Ltd.: key financial ratios
Table 10: Nichi-iko Pharmaceutical: key facts
Table 11: Nichi-iko Pharmaceutical: key financials ($)
Table 12: Nichi-iko Pharmaceutical: key financials (¥)
Table 13: Nichi-iko Pharmaceutical: key financial ratios
Table 14: Sawai Pharmaceutical Co., Ltd.: key facts
Table 15: Sawai Pharmaceutical Co., Ltd.: key financials ($)
Table 16: Sawai Pharmaceutical Co., Ltd.: key financials (¥)
Table 17: Sawai Pharmaceutical Co., Ltd.: key financial ratios
Table 18: Teva Pharmaceutical Industries Limited: key facts
Table 19: Teva Pharmaceutical Industries Limited: key financials ($)
Table 20: Teva Pharmaceutical Industries Limited: key financial ratios
Table 21: Japan size of population (million), 2008–12
Table 22: Japan gdp (constant 2000 prices, $ billion), 2008–12
Table 23: Japan gdp (current prices, $ billion), 2008–12
Table 24: Japan inflation, 2008–12
Table 25: Japan consumer price index (absolute), 2008–12
Table 26: Japan exchange rate, 2008–12

LIST OF FIGURES

Figure 1: Japan generics market value: $ million, 2008–12
Figure 2: Japan generics market volume: % of total pharma volume, 2008–12
Figure 3: Japan generics market geography segmentation: % share, by value, 2012
Figure 4: Japan generics market value forecast: $ million, 2012–17
Figure 5: Japan generics market volume forecast: % of total pharma volume, 2012–17
Figure 6: Forces driving competition in the generics market in Japan, 2012
Figure 7: Drivers of buyer power in the generics market in Japan, 2012
Figure 8: Drivers of supplier power in the generics market in Japan, 2012
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Japan, 2012
Figure 10: Factors influencing the threat of substitutes in the generics market in Japan, 2012
Figure 11: Drivers of degree of rivalry in the generics market in Japan, 2012
Figure 12: Daiichi Sankyo Co., Ltd.: revenues & profitability
Figure 13: Daiichi Sankyo Co., Ltd.: assets & liabilities
Figure 14: Nichi-iko Pharmaceutical: revenues & profitability
Figure 15: Nichi-iko Pharmaceutical: assets & liabilities
Figure 16: Sawai Pharmaceutical Co., Ltd.: revenues & profitability
Figure 17: Sawai Pharmaceutical Co., Ltd.: assets & liabilities
Figure 18: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 19: Teva Pharmaceutical Industries Limited: assets & liabilities

Ask Your Question

Generics in Japan
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: